Rapport Therapeutics (RAPP) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Rapport Therapeutics (NASDAQ: RAPP) recently:

• 10/21/2026 – Rapport Therapeutics had its price target lowered by Wells Fargo & Company from $51.00 to $50.00. They now have an “overweight” rating on the stock.
• 10/21/2026 – Rapport Therapeutics had its price target raised by JonesTrading from $50.00 to $82.00. They now have a “buy” rating on the stock.
• 10/20/2026 – Rapport Therapeutics had its “outperform” rating reaffirmed by Citigroup.
• 10/20/2026 – Rapport Therapeutics had its price target raised by Guggenheim from $65.00 to $70.00. They now have a “buy” rating on the stock.
• 10/20/2026 – Rapport Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial. They now have a $86.00 price target on the stock.
• 10/20/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 10/20/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.
• 10/20/2026 – Rapport Therapeutics had its price target raised by BTIG Research from $75.00 to $89.00. They now have a “buy” rating on the stock.
• 10/15/2026 – Rapport Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Rapport Therapeutics is now covered by UBS Group. They set a “buy” rating and a $71.00 price target on the stock.
• 10/15/2026 – Rapport Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $50.00 price target on the stock.
• 10/14/2026 – Rapport Therapeutics was upgraded by UBS Group to “strong-buy”.
• 10/6/2026 – Rapport Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $65.00 price target on the stock.
• 10/5/2026 – Rapport Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $65.00 price target on the stock.
• 10/5/2026 – Rapport Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $65.00 price target on the stock.
• 9/23/2026 – Rapport Therapeutics was given a new $80.00 price target by UBS Group.
• 9/23/2026 – Rapport Therapeutics had its “market outperform” rating reaffirmed by Citigroup.
• 9/22/2026 – Rapport Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial.
• 9/16/2026 – Rapport Therapeutics had its price target raised by BTIG Research from $65.00 to $75.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other Rapport Therapeutics news, Director Wendy Young acquired 3,789 shares of Rapport Therapeutics stock in a transaction that occurred on Thursday, October 22nd. The shares were acquired at an average cost of $26.39 per share, with a total value of $99,991.71. Following the completion of the purchase, the director directly owned 13,289 shares of the company’s stock, valued at $350,696.71. This represents a 39.88% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director John Maraganore bought 9,411 shares of the firm’s stock in a transaction on Thursday, October 22nd. The stock was acquired at an average price of $26.45 per share, for a total transaction of $248,920.95. Following the transaction, the director owned 9,411 shares of the company’s stock, valued at approximately $248,920.95. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 61,694 shares of company stock valued at $1,664,818 and sold 100,186 shares valued at $4,484,793. 12.48% of the stock is owned by corporate insiders.

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.